FDA panel votes in favour of approving terlipressin for the treatment of adults hepatorenal syndrome

The New Drug Application included the results of a Phase III study (CONFIRM) in which it met the primary endpoint of verified HRS Reversal (renal function improvement, avoidance of dialysis and short-term survival; achieved in 29.1% versus 1.8% of those randomised to placebo).


Biospace Inc.